Form 4: Aadi Bioscience Chief Scientific Officer Acquires Stock Options

David Dornan, Chief Scientific Officer of Aadi Bioscience, Inc., reports the acquisition of stock options.

Summary

• David Dornan, the Chief Scientific Officer of Aadi Bioscience, Inc., filed a Form 4 on March 4, 2025, reporting a transaction.
• Dornan acquired stock options to purchase 687,979 shares of Aadi Bioscience common stock at an exercise price of $2.305 per share.
• These options vest over four years, starting with 25% vesting on the one-year anniversary of the Vesting Commencement Date (February 18, 2025), and the remainder vesting monthly thereafter.
• The options expire on March 4, 2035.
• Following the reported transaction, Dornan directly owns 687,979 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither particularly positive nor negative on its own.

Positives

• The acquisition of stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule implies a continued service commitment from the reporting person.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions in publicly traded companies. This filing indicates changes in beneficial ownership of Aadi Bioscience's securities by one of its officers.

Key Dates